Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study
Standard
Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study. / Abraham, Ivo; MacDonald, Karen; Tharmarajah, Soba; Bokemeyer, Carsten; Ludwig, Heinz; Soubeyran, Pierre; Battistel, Vittorio; Aapro, Matti.
in: J GERIATR ONCOL, Jahrgang 4, Nr. 2, 01.04.2013, S. 196-201.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study
AU - Abraham, Ivo
AU - MacDonald, Karen
AU - Tharmarajah, Soba
AU - Bokemeyer, Carsten
AU - Ludwig, Heinz
AU - Soubeyran, Pierre
AU - Battistel, Vittorio
AU - Aapro, Matti
N1 - Copyright © 2012 Elsevier Inc. All rights reserved.
PY - 2013/4/1
Y1 - 2013/4/1
N2 - INTRODUCTION: The Anemia Cancer Treatment study assessed hemoglobin (Hb) outcomes following treatment with erythropoiesis-stimulating agents (ESA) in anemic (Hb≤11g/dL) patients in Europe. We replicated the original analyses stratifying by age, namely patients aged ≥70 (n=637) versus those aged<70 (n=1555).MATERIALS AND METHODS: A secondary analysis of Hb outcomes was assessed over 8-10weeks. Treatment response criteria included increases of Hb≥1g/dL, Hb≥1g/dL over 8weeks, and Hb≥2g/dL over the course of the study period.RESULTS: Mean Hb increased from similar levels of 9.5g/dL [p=not significant (ns)] at visit one to 10.9g/dL (p=ns) at visit three (both p<0.001). Patients aged≥70 had higher mean Hb at visit two (10.6g/dL vs. 10.3g/dL, p<0.001). Cohorts did not differ in treatment response rates (all p=ns). Mean performance status differed between cohorts at each visit (all p≤0.011); both groups showed significant improvements (both p<0.001). Immediacy of response was a consistent determinant but was more pronounced among patients aged≥70. Less consistent determinants included performance status in the age≥70 group, as well as hematological malignancy and Hb at ESA start in the age<70 group. The proportion of variance in Hb outcomes attributable to treatment center ranged from 0.090 to 0.289 in the age≥70 cohort and 0.126 to 0.361 in the age<70 cohort.CONCLUSIONS: Both groups achieved similar Hb levels with the age≥70 cohort showing a higher initial evolution rate and potentially a different Hb response trajectory. Patients age≥70 were more likely to benefit from ESAs if showing an early erythropoietic response and exhibiting no or little impairment in performance status. Differential attribution of variability in older vs. younger adults suggests that individualization of ESA therapy may facilitate Hb response in geriatric patients with cancer.
AB - INTRODUCTION: The Anemia Cancer Treatment study assessed hemoglobin (Hb) outcomes following treatment with erythropoiesis-stimulating agents (ESA) in anemic (Hb≤11g/dL) patients in Europe. We replicated the original analyses stratifying by age, namely patients aged ≥70 (n=637) versus those aged<70 (n=1555).MATERIALS AND METHODS: A secondary analysis of Hb outcomes was assessed over 8-10weeks. Treatment response criteria included increases of Hb≥1g/dL, Hb≥1g/dL over 8weeks, and Hb≥2g/dL over the course of the study period.RESULTS: Mean Hb increased from similar levels of 9.5g/dL [p=not significant (ns)] at visit one to 10.9g/dL (p=ns) at visit three (both p<0.001). Patients aged≥70 had higher mean Hb at visit two (10.6g/dL vs. 10.3g/dL, p<0.001). Cohorts did not differ in treatment response rates (all p=ns). Mean performance status differed between cohorts at each visit (all p≤0.011); both groups showed significant improvements (both p<0.001). Immediacy of response was a consistent determinant but was more pronounced among patients aged≥70. Less consistent determinants included performance status in the age≥70 group, as well as hematological malignancy and Hb at ESA start in the age<70 group. The proportion of variance in Hb outcomes attributable to treatment center ranged from 0.090 to 0.289 in the age≥70 cohort and 0.126 to 0.361 in the age<70 cohort.CONCLUSIONS: Both groups achieved similar Hb levels with the age≥70 cohort showing a higher initial evolution rate and potentially a different Hb response trajectory. Patients age≥70 were more likely to benefit from ESAs if showing an early erythropoietic response and exhibiting no or little impairment in performance status. Differential attribution of variability in older vs. younger adults suggests that individualization of ESA therapy may facilitate Hb response in geriatric patients with cancer.
KW - Age Factors
KW - Aged
KW - Anemia
KW - Female
KW - Hematinics
KW - Hemoglobins
KW - Humans
KW - Male
KW - Middle Aged
KW - Multicenter Studies as Topic
KW - Neoplasms
KW - Outcome Assessment (Health Care)
KW - Retrospective Studies
U2 - 10.1016/j.jgo.2012.09.058
DO - 10.1016/j.jgo.2012.09.058
M3 - SCORING: Journal article
C2 - 24071545
VL - 4
SP - 196
EP - 201
JO - J GERIATR ONCOL
JF - J GERIATR ONCOL
SN - 1879-4068
IS - 2
ER -